David Marek is the founder of Myovant Sciences. Myovant Sciences has raised $1.7B in total funding. Latest round: Conventional Debt.
David Marek is the Chief Executive Officer of Myovant Sciences, Inc. Myovant Sciences is a company focused on developing treatments for women's health diseases and endocrine-related disorders. The company's drug pipeline includes Relugolix, which is being developed for uterine fibroids, endometriosis, and prostate cancer. Myovant Sciences has received FDA approval for MYFEMBREE®, a once-daily treatment for heavy menstrual bleeding associated with uterine fibroids.
Full founder directory · Investor directory · Company funding database · Fundraising library